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Background: Hypermethylation of the fragile X mental retardation 1 gene FMR1 results in decreased expression of
FMR1 protein FMRP, which is the underlying cause of Fragile X syndrome – an incurable neurological disorder
characterized by mental retardation, anxiety, epileptic episodes and autism. Disease-modifying therapies for Fragile
X syndrome are thus aimed at treatments that increase the FMRP expression levels in the brain. We describe the
development and characterization of two assays for simple and quantitative detection of FMRP protein.
Method: Antibodies coupled to fluorophores that can be employed for time-resolved Förster’s resonance energy
transfer were used for the development of homogeneous, one-step immunodetection. Purified recombinant
human FMRP and patient cells were used as control samples for assay development.
Results: The assays require small sample amounts, display high stability and reproducibility and can be used to
quantify endogenous FMRP in human fibroblasts and peripheral blood mononuclear cells. Application of the assays
to FXS patient cells showed that the methods can be used both for the characterization of clinical FXS patient
samples as well as primary readouts in drug-discovery screens aimed at increasing endogenous FMRP levels in
human cells.
Conclusion: This study provides novel quantitative detection methods for FMRP in FXS patient cells. Importantly,
due to the simplicity of the assay protocol, the method is suited to be used in screening applications to identify
compounds or genetic interventions that result in increased FMRP levels in human cells.
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With an estimated prevalence of 1 in 4,000, Fragile X syn-
drome (FXS) is the most prevalent monocausal inherit-
ed mental retardation disorder [1]. The disorder’s clinical
symptoms include intellectual and cognitive impairment,
hyperactivity and increased overall anxiety as well as early-
life epilepsy episodes and autism [2]. The underlying causa-
tive mutation in almost all FXS patients is the expansion of
a CGG triplet repeat expansion in the 5′ UTR of the fragile
X mental retardation 1 gene FMR1, correlating with hyper-
methylation of the repeat region and the upstream FMR1
promoter. This epigenetic modification in turn results in* Correspondence: Andreasweiss@Email.com
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reproduction in any medium, provided the ortranscriptional silencing with reduced expression levels of
FMR1 mRNA and its protein product, the FMR1 protein
FMRP [3]. In addition to the triplet repeat expansion in the
noncoding region, a small subset of about 2% of all FXS
cases are caused by mutations in the coding region of the
gene that also result in reduced or absent FMRP protein ex-
pression [4,5].
FMRP is a 71 kDa predominantly cytoplasmatic RNA
binding protein [6] with high expression levels in the post-
synaptic regions of the central nervous system, where it is
associated with polyribosomes and represses the local
translation of mRNAs [7]. Absence or decreased postsyn-
aptic FMRP levels in turn lead to hyperactivity of metabo-
tropic glutamate receptor 5 (mGluR5)-mediated synaptic
pathways. This results in altered dendritic spines at the
histological levels and the clinically observed cognitive
and behavioral abnormalities in FXS patients [8]. Animalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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duction in mGluR5 expression showed a rescue of be-
havioral deficits [9] and early findings in clinical trials
suggest that behavioral deficits can be reduced by
treatment with selective mGluR5 inhibitors in a subset
of patients with full methylation of the FMR1 promoter
region [10]. However, despite those encouraging re-
sults, mGluR5-directed approaches remain symptom-
atic treatments that do not target the underlying
disease cause – decreased postsynaptic levels of FMRP
in the central nervous system. The further identifica-
tion of disease-modifying therapies that can increase
the postsynaptic FMRP levels will thus rely on the de-
velopment of quantitative and screening compatible
readouts.
Current reported methods for FMRP level analysis in-
clude immunohistochemical, protein immunoblot and
ELISA assays [11,12]. While those techniques greatly im-
proved our insights into FXS, they are either semiquan-
titative in nature or prove to be too labor intensive,
containing multiple protocol steps that limit their use for
screening of larger compound and genomic libraries in a
microtiter plate format. To circumvent these limitations,
we developed an alternative high-throughput compatible
robust and sensitive endogenous FMRP quantification im-
munoassay utilizing time-resolved Förster’s resonance en-
ergy transfer (TR-FRET). TR-FRET technology is based
on simultaneous in-solution binding of two fluorophore-
labeled antibodies to their antigen. Antibody binding to
their antigen brings the fluorophores in close enough
proximity for a TR-FRET to occur after excitation of the
donor fluorophore. This method has the advantages that,
due to its homogeneous nature, only a single pipetting
step is needed for detection and the use of low sample vol-
umes greatly facilitates microtiter screens aimed at identi-
fying compounds or genes that modify target protein
levels. Indeed, similar methods based on TR-FRET im-
munoassay detection have been previously reported in
protein-level modifying screens for other neurological dis-
orders such as Parkinson’s disease [13].Methods
Antibodies
N-terminal-specific anti-FMRP 1C3 (catalogue num-
ber Mab2160) was obtained from Millipore (Billerica,
MA, USA), and N-terminal-specific anti-FMRP (M03)
clone 3E11 (catalogue number H00002332-M03) was
obtained from Abnova (Taipei City,Taiwan). C-terminal-
specific anti-FMRP antibody (catalogue number F4055)
was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Antibody labeling with Lumi4W-Tb (−Tb) or d2 (−d2)
fluorophores was performed by Cisbio Bioassays (Codolet,
France).Epitope mapping
Epitope mapping for TR-FRET antibodies was performed
by peptide blot. The peptide blot covering the FMRP se-
quence with peptides 20 amino acids long with a se-
ven amino acid overlap was obtained from Jpt (Berlin,
Germany). After reactivation according to the manual,
the membrane was blocked with 5% skim milk powder
in Tris-buffered saline Tween-20 (TBST) and incubated
with anti-FMRP antibody from Millipore (1:500 in 0.5%
skim milk in TBST) overnight. The membrane was
washed three times and incubated with secondary anti-
body for 1 hour and developed using enhanced chemilu-
minescence (GE Healthcare, Fairfield, CT, USA).
Production, purification and characterization of
recombinant FMRP
Escherichia coli strain BL21(DE3) harboring the ex-
pression plasmid for MBP-FMRP was cultivated at
37°C in Terrific Broth (TB) medium modified with
4-Morpholinepropanesulfonic acid (MOPS), and sup-
plemented with 100 μg/ml ampicillin. MBP-FMRP in-
duction was started by adding 0.5 mM IPTG at an
OD600 of 0.55 overnight at 16°C. Cells were harvested
by centrifugation and all subsequent purification steps
were done at room temperature using the Äkta Avant
system (GE Healthcare, Fairfield, CT, USA). Cells were
resuspended in 500 ml of 50 mM Tris/HCl buffer, pH
8.0, containing 150 mM NaCl and 1 mM Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP). Then 1
μl Benzonase (Sigma-Aldrich (St. Louis, MO, USA))
was added with complete protease inhibitor tabs
(Roche Diagnostics AG, Rotkreuz, Switzerland). Cells
were ruptured using a French press and the homogen-
ate was centrifuged at 8000×g for 30 minutes at 4°C.
The sample was loaded on 3 ml MBP-Trap HP column
(GE Healthcare) and the column was washed with 50
mM Tris/HCl, pH 8.0, buffer containing 150 mM NaCl
and 1 mM TCEP. MBP-FMRP protein was eluted with
50 mM Tris/HCl, pH 8.0, buffer containing 10 mM
Maltose, 150 mM NaCl and 1 mM TCEP. Fractions
containing the protein were pooled and concentrated
using Amicon concentrators with 30 kDa cutoff size
(Millipore). Finally, MBP-FMRP solution was applied
to a size exclusion chromatography column (Superdex
200, HiLoad 16/60; GE Healthcare), equilibrated with
50 mM Tris/HCl, pH 8.0, buffer containing 1 M NaCl,
1 mM TCEP, 1 mM ethylenediamine tetraacetic acid
and 5% glycerol at a flow rate of 1 ml/minute. The frac-
tions containing the purified protein were pooled. The
pooled solution was analyzed by SDS-Coomassie blue
gel, immunoblotting and HPLC. A Poros R1 column
(Agilent Technologies, Inc., Santa Clara, CA, USA)
with a flow rate of 1.2 ml/minute was used for HPLC
with buffer A being H2O with 0.1% TFA and buffer B
Schutzius et al. Journal of Neurodevelopmental Disorders 2013, 5:8 Page 3 of 9
http://www.jneurodevdisorders.com/content/5/1/8being acetonitrile with 0.1% TFA. MBP-FMRP was
eluted by increasing the acetonitrile concentration
from 5 to 95% in 6.7 minutes with a pressure limit of
170 bar.
SDS-PAGE and immunoblot analysis
Cells were lysed in M-PERW lysis buffer (Pierce Biotech-
nology, Inc., Rockford, IL, USA) supplemented with 150
mM NaCl and Protease Inhibitors (Roche Diagnostics AG,
Rotkreuz, Switzerland). After protein quantification with
BCA Assay (Pierce Biotechnology, Inc.), equal amounts of
protein were loaded on NuPage 4 to 12% Bis–Tris gels
and electrophoresis was performed according to the man-
ual. The gel was blotted on a polyvinylidene fluoride mem-
brane (Immobilon-P; Millipore), blocked with 5% skim
milk powder in TBST for 1 hour at room temperature and
incubated overnight with primary antibodies. Membranes
were washed and incubated with secondary antibody for 1
hour and were developed using enhanced chemilumines-
cence (GE Healthcare).
Cellular models
Hek293T cells were grown at 37°C in 5% CO2 in
Dulbecco’s minimum essential medium (DMEM +
GlutaMAX) supplemented with 10% fetal bovine serum
(Life Technologies Ltd, Paisley, UK). For FMRP over-
expression, cells were transiently transfected with Myc-
DDK-tagged FMRP (OriGene, Rockville, MD, USA) using
Lipofectamine 2000 (Life Technologies Ltd). Primary hu-
man fibroblasts of healthy control patients (ID: BJ1) or
FXS patients (ID: GM 09497) were obtained from ATCC
(Manassas, VA, USA) and Coriell (Camden, NJ, USA) re-
spectively and cultured in Eagle’s minimum essential
medium (Sigma-Aldrich) supplemented with 15% fetal bo-
vine serum, GlutaMAX, penicillin and streptomycin (Life
Technologies Ltd).
Time-resolved Förster’s resonance energy transfer
For TR-FRET, 5 μl sample/well was loaded on a 384-well
low-volume polystyrene microtiter plate (Greiner Bio-
One GmbH, Kremsmünster, Austria). After addition of 1
μl antibody solution (50 mM NaHPO4, 400 mM NaF,
0.1% BSA, and 0.05% Tween-20) containing Millipore
Anti-FMRP-Tb antibody in combination with Abnova
Anti-FMRP-d2 or Sigma Anti-FMRP-d2 in the indica-
ted concentrations per well, plates were incubated for
20 hours at room temperature. Time-resolved FRET
was determined using an Envision reader (Perkin Elmer,
Inc., Waltham, MA, USA). After excitation at 320 nm,
antigen-specific energy transfer was calculated as the ra-
tio of the emission of the acceptor fluorophore d2 (665
nm) and that of the donor fluorophore Tb (620 nm).
FMRP levels are presented as ΔF values, which
normalize the emission of the TR-FRET signal of theacceptor fluorophore (665 nm) to that of the FRET-
independent donor fluorophore (620 nm) taking into ac-
count the background fluorescence of the assay for both
channels. ΔF is therefore the percentage signal over
assay buffer background and is given by the equation:
ΔF ¼ 100 Ratio665=620Sample  Ratio665=620Backgroundblank
Ratio665=620Backgroundblank
Time-resolved Förster’s resonance energy transfer assay
in 384-well plate format
For direct high-throughput compatible quantification of
endogenous FMRP levels in human fibroblasts, cells were
plated the previous day at indicated cell numbers into
384-well plates (Greiner Bio-One GmbH). Medium was
removed and directly lysed without prior washing with 6.5
μl M-PER lysis buffer (Pierce Biotechnology, Inc.) sup-
plemented with 150 mM NaCl and Protease Inhibitors
(Roche Diagnostics AG). For detection of endogenous
FMRP levels in human peripheral blood mononuclear
cells (PBMCs), PBMC pellets were lysed with M-PER lysis
buffer supplemented with 150 mM NaCl and protease in-
hibitors for 30 minutes at 4°C under shaking. For both
cell types, 5 μl lysate was then transferred into white,
opaque 384-well low-volume polystyrene microtiter plates
(Greiner Bio-One GmbH) and TR-FRET quantification
was performed as described above.
Limit of detection determination
Limit of detection (LoD) levels for the indicated TR-FRET
antibody assays were determined according to guidelines
from the Clinical and Laboratory Standards Institute [14].
The LoD is defined as:
LoD ¼ LoBþ 1:645SDlowest concentration sample
This LoD describes the lowest analyte concentration,
reliably being distinguishable from the limit of blank
(LoB):
LoB ¼ meanblank þ 1:645SDblank
The LoB was determined by measurement of a mini-
mum of 20 replicates containing assay buffer and anti-
bodies. The LoD was then quantified with repeated
measurements of the indicated concentrations of puri-
fied FMRP for which ≥95% of the observed signal was
higher than the LoB corresponding to the used detection
antibody pair.
Statistical analysis
FMRP levels are presented as averages with standard de-
viations. The Z´-factor was calculated according to [15].
Schutzius et al. Journal of Neurodevelopmental Disorders 2013, 5:8 Page 4 of 9
http://www.jneurodevdisorders.com/content/5/1/8Results and discussion
To aid in the development of a homogeneous TR-FRET
immunoassay for FMRP we first generated the isolated
protein by bacterial expression and subsequent column
purification. Purified FMRP has been previously reported
to be prone for aggregation and precipitation, limiting
its use as a stable protein standard. These protein in-
stabilities can be addressed by fusing the maltose bind-
ing protein MBP to the FMRP N-terminus [11]. We thus
opted to use MBP-FMRP protein as our isolated ana-
lyte standard. Purity and concentration or MBP-FMRP
was determined with SDS-gel, protein immunoblot and
HPLC (Additional file 1: Figure S1). The purified protein
was used in the following assay development steps.
A previous publication reports the successful use of
two defined FMRP epitopes for detection using an
ELISA method [11]. We thus next tested whether anti-














































Figure 1 Assay condition optimization for detection of human FMRP
recombinant FMRP (5 ng) in a 1 ng/μl concentration were analyzed by two
immunoassays using an antibody combination detecting a N-terminal and
combination of antibodies in which both detect N-terminal epitopes (N-N,
stronger signal over background detection. (B) Antibody titer optimization
FMRP (5 ng). (C) Optimization of TR-FRET assay conditions for time and tem
temperature incubation overnight (≥20 hours). All values presented as perc
represent averages and standard deviations of triplicates.against a N-terminal epitope, F4055 raised against a
C-terminal epitope) would also be functional when labeled
and utilized in a TR-FRET immunoassay setup. Using this
antibody combination in an unoptimized protocol with 1
ng/well Mab2160-Tb and 10 ng/well F4055-d2 incubation
for 2 hours at room temperature, a small but FMRP-
specific detection signal was observed when using 1 ng/μl
purified MBP-FMRP as antigen (Figure 1A, N-C). Since
the signal strength of TR-FRET detection is closely related
to the distance of the antigen-binding antibodies, we asked
ourselves whether substitution of the C-terminal F4055-
d2 acceptor antibody against a more N-terminally binding
antibody would result in a stronger TR-FRET signal in
combination with the N-terminal Mab2160 antibody.
Since the epitope for Mab2160 has not yet been defined in
detail and to avoid testing a N-terminal antibody combin-
ation that competed for the same epitope, we thus
































by time-resolved Förster’s resonance energy transfer. (A) Purified
different time-resolved Förster’s resonance energy transfer (TR-FRET)
a C-terminal FMRP epitope (N-C, Mab2160-Tb + SigmaF4055-d2) or a
Mab2160-Tb + M03-d2). N-N antibody combination resulted in
for N-C and N-N combination for detection of purified recombinant
perature of incubation. Both assays performed best at room
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N-N (Mab2160-Tb + M03-d2)
a: protein and antibody dilutions stored at 4°C and reused
b: protein dilution stored at 4°C and reused, new antibody dilution
c:  new protein dilution,new antibody dilution
Figure 2 (See legend on next page.)
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Figure 2 TR-FRET assay characterization for reliability, robustness and reproducibility. (A) Dynamic range of both time-resolved Förster’s
resonance energy transfer (TR-FRET) assays was assessed by serial dilutions of purified recombinant FMRP starting at 2,000 pg/μl into assay buffer
in wells of low-volume 384-well plates. (B) Limits of detection for both assays were determined according to the standards set by the Clinical and
Laboratory Standards Institute [12]. The TR-FRET signal intensity for FMRP protein concentrations around the expected putative limits of detection
(as previously examined in the dynamic range assessment) were compared with the limit of blank for each assay. Limit of detection was defined
as the FMRP concentration at which ≥95% of analyzed samples resulted in a TR-FRET signal above the limit of blank. Determined limit of
detection concentrations for each assay are indicated by grey symbols. (C) Assessment of intra-assay variability for each assay with three different
FMRP concentrations distributed randomly across a low-volume 384-well plate (locations I to III). (D) Assessment of inter-assay variability was
determined for each assay by testing reused frozen and thawed protein standard and antibodies (a), reused protein standard but fresh antibody
detection solution (b) or freshly diluted protein standard and antibody solution (c) on two independent days. All values for A, C and D are
presented as percentage signal over assay buffer background. All data and error bars represent averages and standard deviations of triplicates.
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quence (Additional file 2: Figure S2).
After having identified the Mab2160 binding region on
FMRP as amino acids 34 to 39, we proceeded to combine
the antibody with the N-terminally binding antibody
Abnova-M03 whose described epitope (amino acids 121
to 220) is in proximity to but is not overlapping with
Mab2160. This antibody combination indeed resulted in a
stronger and specific FMRP detection signal (Figure 1A,
N-N). We continued to perform all further assay opti-
mization and characterization steps with both antibody
combinations in order to establish two different TR-FRET
detection assays for FMRP.
The antigen-specific TR-FRET signal is determined as
the ratio of the emission wavelengths specific for the ac-
ceptor fluorophore d2 (665 nm) and the donor fluoro-
phore Tb (620 nm) coupled to the respective antibodies
used. Using purified MBP-FMRP as analyte, we thus first
optimized the assay conditions for the titers of donor-
acceptor antibodies per well (Figure 1B). Having identified
the ideal antibody concentrations for the N-C-terminal
(0.5 ng/well Mab2160-Tb + 20 ng/well F4055-d2) as well
as the N-N-terminal antibody combination (0.5 ng/well
Mab2160-Tb + 5 ng/well M03-d2), we proceeded to assess
the assay kinetics for incubation temperature and time
(Figure 1C).
After optimization of these parameters, the assay per-
formance was characterized for dynamic range, lower
limit of detection as well as intra-assay and inter-assay
stability. Dilution series with purified protein showed a
dynamic range of about three orders of magnitude for
both assays with linear signals up to 2,000 pg/μl MBP-
FMRP (Figure 2A). The LoD for the assays was deter-
mined by assessing the protein concentration by which
95% of samples delivered a signal above the assay buffer
LoB [14]. The LoD was calculated as 40 pg/μl for the
N-C-terminal antibody combination and 10 pg/μl MBP-
FMRP for the N-N-terminal antibody combination
(Figure 2B). High intra-plate and inter-plate stability of
the assays – a prerequisite for high-throughput screen-
ing – was verified by distributing technical replicates of
different MBP-FMRP dilutions across random wells of384-microtiter plates and repeating the assay on inde-
pendent days with either stock or fresh dilutions of anti-
gen and antibodies (Figure 2C,D).
After these assay characterization steps with puri-
fied antigen, we proceeded to optimize the lysis buffer
conditions for FMRP protein expressed in cells. We
transfected HEK293 cells with human FMRP or mock
plasmids and verified FMRP overexpression over en-
dogenous FMRP levels present in HEK cells by pro-
tein immunoblot (Additional file 3: Figure S3A). Equal
amounts of mock and FMRP transfected HEK cells were
then lysed with six different lysis buffers and the FMRP
signal intensity was determined using the N-N-terminal
antibody TR-FRET pair (Additional file 3: Figure 3B).
After optimization of the lysis conditions for efficient
FMRP extraction from cells and TR-FRET assay com-
patibility, we determined the linearities and recovery
rates for FMRP in a relevant biological matrix. We thus
spiked recombinant FMRP protein into lysate of FXS
patient-derived fibroblasts. Both assays exhibited excel-
lent linearity and recover rates for human FMRP protein
(Figure 3A,B) when spiked into a complex biological
matrix void of detectable endogenous FMRP protein
levels (Figure 3C). Next, we investigated whether the more
sensitive N-N-terminal antibody combination was cap-
able of robustly quantifying endogenous human FMRP
levels from batch lysates of a healthy control over a FXS
patient-derived fibroblast line (Figure 3D). Endogenous
FMRP was readily detected in healthy human control fi-
broblasts line when compared with FXS patient cells.
Having determined the proof-of-principle that the opti-
mized homogeneous TR-FRET assay can be used to ac-
curately detect endogenous FMRP protein in batch
lysates of human material, we assessed whether detec-
tion was also feasible in fibroblasts grown and lysed dir-
ectly in a 384-well microtiter plate, a format commonly
used for compound or genetic screens (Figure 3E). Z′-
factor values of 0.85 for 8,000 seeded cells/well and 0.72
for 4,000 seeded cells/well indicated the assay’s capabil-
ity to be used in unbiased screening efforts to identify
treatments aimed at increasing FMRP levels in FXS
patient-derived fibroblasts.
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Figure 3 Assay performance and application for endogenous human FMRP in fibroblasts. (A) Determination of time-resolved Förster’s
resonance energy transfer (TR-FRET) assay linearities for purified FMRP when spiked into a fibroblast lysate from a Fragile X syndrome (FragileX)
patient without any detectable endogenous FMRP levels. (B) Recovery rate calculations of FMRP protein in FragileX patient lysate based on
expected versus quantified FMRP values. (C) Immunoblot for endogenous human FMRP protein in lysates from a healthy control or a FragileX
patient. (D) Detection of endogenous human FMRP by the N-N-antibody TR-FRET assay in 5 μl sample volume in low-volume 384-well plate
format for serial dilutions of lysates from a healthy control and a FragileX patient. (E) Quantification of endogenous FMRP in healthy control
versus FragileX patient fibroblast lines grown and lysed in 384-well plates. (F) Detection of endogenous FMRP in peripheral blood mononuclear
cell (PBMC) lysates of healthy human control volunteers by the N-N-antibody combination in the low-volume 384-well plate format. Total protein
concentrations per well are indicated. Purified MBP-FMRP protein (5 ng) was used as control. (G) Comparison of FMRP detection signal in PBMC
lysates of healthy control patients versus PBMC lysate obtained from a FragileX patient (1.65 μg total protein loaded per well for each sample).
Values for A, D, E, F and G presented as percentage signal over assay buffer background. All data and error bars represent averages and standard
deviations of triplicates.
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able for the detection of endogenous FMRP in PBMCs, a
cellular population easily accessible in clinical practice,
we next analyzed serial dilutions of human PBMC ly-
sates from healthy control volunteers. In agreement with
the FMRP detection in human fibroblasts, endogenous
FMRP was readily quantified in all PBMC lysates from
healthy control subjects in a linear manner (Figure 3F)
whereas FMRP detection signal was markedly reduced
in a PBMC preparation of a FXS patient (Figure 3G).
Some caveats of the assay require further investigation
in future studies. First, FXS is a neurological retardation
disorder with the underlying pathomechanism likely to be
a result of decreased postsynaptic levels of FMRP [7],
which in turn are caused by hypermethylation of the
FMR1 promoter [3]. It is currently unknown whether this
epigenetic modulation pattern or the enzymatic machinery
required for possible demethylation is comparable in post-
mitotic neuronal cell populations and proliferating cells
such as the fibroblasts used in this study. Future studies
using FXS patient fibroblast iPS-derived neurons could
help to better understand this question and to elucidate
whether screening for FMRP level increase in fibroblast
lines will translate into efficacy in neurons. Second, while
the signal-to-background value and Z′ factor of our assay
can be assessed by comparing endogenous wild-type
FMRP expression levels in healthy control fibroblasts ver-
sus FXS patient-derived fibroblasts, a more informative
comparison would have been to assess the effect of an
established tool compound known to increase FMRP
levels in FXS patient cells versus dimethyl sulfoxide mock
control. Indeed, SIRT1 inhibition by splitomicin and treat-
ment with the cytosine nucleoside analogue 5-azacytidine
have been reported to increase FMR1/FMRP levels in
patient cells [16,17]. However, a closer analysis of the re-
ported data limited their use as tool compounds for a
screening format for the following reasons. First, the sig-
nificant increases of FMRP levels with those treatments
have only been achieved by using prolonged treatment du-
rations of 3 to 10 days with constant renewal of cell cul-
ture medium during culture. Such a repeated medium
change with diluted compounds and long culture times of
a proliferative cell line is not suitable in the 384-well mi-
crotiter plate high-throughput screening mode. Second,
even when treating for these prolonged periods, the
reported increase in FMR1 transcript levels in FXS patient
cell lines reached only up to ~20% of healthy control
levels. Indeed, 24-hour 5-azacytidine treatment which is
more comparable and amendable to screening conditions
only resulted in an increase of FMR1 levels to 4% of that
of healthy controls, a change likely to small to be detected
in a microtiter plate format with statistical significance
[16]. Third, the observed maximum treatment effect of
up to 20% of normal levels was restricted to somelymphoblast lines from selected patients while the effect
was much lower or even absent in other lymphoblast or
fibroblast cell lines derived from other FXS patients, a re-
sult attributed to differential methylation status of the pa-
tients FMR1 promoter regions. It should be pointed out
that these above-described limitations can be attributed to
so far unanswered biological questions in the FXS field
and are not limitations resulting from the intrinsic tech-
nical principle of our assay. We thus feel confident that
with the continuously increasing knowledge for this devas-
tating neurological disorder, these open questions will be
addressed.
Conclusion
In summary, we describe the development of novel micro-
titer TR-FRET immunoassays for the quantification of
FMRP. These assays are robust, reliable and reproducible
and require only small sample volumes for quantification
of endogenous FMRP in human cells. Importantly, the as-
says distinguish themselves from alternative FMRP immu-
noassays that require sequential and labor-intensive
capture and detection steps, which renders them impracti-
cal for high-throughput screens. Owing to the simplicity
of the TR-FRET assay protocol, the herein described assays
are suitable for medium-throughput to high-throughput
screening efforts that aim to find genetic modifiers or
compounds that increase FMRP levels in FXS patient-
derived cell lines.
Additional files
Additional file 1: Figure S1. Purification and characterization of
recombinant MBP-FMRP protein. (A) Bacterial expressed MBP-FMRP
protein was analyzed by Coomassie blue staining on SDS-PAGE gel. Two
main bands are visible after pooling fractions eluted from a MBP-Trap HP
column. (B) MBP-FMRP protein analyzed by immunoblot with C-terminal
anti-FMRP (Sigma-Aldrich, St. Louis, MO , USA) and N-terminal anti-FMRP
(Abnova , Taipei City, Taiwan). Both main bands identified via Coomassie
gel represent purified recombinant FMRP protein, with the lower band
being a proteolytic N-terminal fragment only detectable by the
N-terminal antibody. (C) HPLC analysis of protein verifies high purity of
the recombinant FMRP isolated from bacterial cultures.
Additional file 2: Figure S2. Mapping of the N-terminal Mab2160
epitope. (A) A peptide blot covering the whole human FMRP sequence
in peptides 20 amino acids long with a seven amino acid overlap was
subjected to Mab2160 incubation with subsequent immunoblot
detection. (B) Mab2160 epitope was identified as amino acids 34–39
(NNWQPD).
Additional file 3: Figure S3. Optimization of cell lysis conditions for
subsequent TR-FRET detection of human FMRP protein. (A) Human FMRP
protein was transiently expressed in HEK293 cells. Increased expression
over endogenous levels was verified with immunoblot. (B) Equal
amounts of FMRP or mock transfected HEK293 cells were lysed with
different lysis buffers as indicated. Lysates were analyzed by TR-FRET for
FMRP levels after normalization to total protein content.
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